

OVARIAN CANCER


Epithelial ovarian cancer is the fourth largest killer of women after breast cancer.

Due to the absence of overt symptoms, the majority of cases (70%) are diagnosed at an advanced stage (Stage III/IV) (Rosenthal & Jacobs, 1998).

With late stage disease, the average 5-year survival rate is 12-27%. If, however, ovarian cancer is detected early, 5-year survival is dramatically improved (86% for Stage I).

The key factor in reducing the disease-associated mortality is earlier diagnosis.

At HealthLinx, we have developed a multimarker blood test for ovarian cancer (OvPlex™) that significantly improves detection of both early and late stage ovarian cancer.



● STAGE I ● STAGE II ● STAGE III ● STAGE IV

5-Year Survival Rate (% surviving) by Stage (I - IV) of ovarian cancer at the time of diagnosis (from Nguyen et al. 1993)

OvPlex™ - INFORMATION


HealthLinx Limited

EARLY STAGE DISEASE

The model set used included all stages of the disease to more accurately represent the population and the validation set included only early stage samples plus controls (non disease samples).

The result was that OvPlex™ outperformed CA125 across all the key indicators and identified ovarian cancer patients that were not identified by CA125.

On the trial data set there is strong evidence of the superiority of the OvPlex™ diagnostic over CA125.



Model set remains the same and Validation set contains **only Early Stage (Stage I/II) Disease** samples

OvPlex™ - INFORMATION

HealthLinx Limited

The overall performance of OvPlex™ is significantly better than CA125 for the diagnosis of ovarian cancer

Assay Performance Measures	CA125	OvPlex™
Sensitivity	92.6	94.1
Specificity	89.6	91.3
Overall accuracy	91.1	92.7

Calculated at an OvPlex™ cutoff value of 0.3

- OvPlex™ identified more patients than CA125 who had ovarian cancer
- OvPlex™ eliminated more patients who were misclassified with the disease than CA125
- Independent bio-statistical analysis demonstrates that the performance of OvPlex™ is statistically better than CA125